About This Manual

What this site is

Telehealth PT-141 is a reference manual on the peer-reviewed research about bremelanotide (PT-141) and on the regulatory framework that governs its telemedicine prescribing. It reads the literature and the federal and state documents and lays them out; it does not act on them. Nothing here is a clinic. No clinician is on staff, and no medical advice, evaluation, consultation, diagnosis, or treatment is provided. Nothing is manufactured, sold, or distributed — including any bremelanotide preparation. What the manual contains is a reading of publicly available science and publicly available regulatory record.

The domain carries the word 'telehealth' because the manual's subject is the telehealth pathway for bremelanotide — how qualified clinicians evaluate and prescribe it remotely under federal and state law. The modifier describes the manual's subject and stance toward the documents. It is not a claim that telehealth services are provided here.

Editorial standards and sourcing

Every quantitative claim in the manual is sourced to a published study or regulatory document. Priority sources, in approximate order: the FDA-approved prescribing information (DailyMed and accessdata.fda.gov); peer-reviewed clinical trials (PubMed-indexed journals); systematic reviews and professional-society guidelines (ICSM, ACOG, ISSWSH, ISSM); the National Library of Medicine's LiverTox monograph series; and HHS / Telehealth.gov for regulatory baseline. Product marketing pages, vendor materials, and social-media posts are not cited. Preprints are not cited unless the topic specifically demands current-but-uncommitted research and the preprint is clearly labeled.

The manual links to no commercial vendors of bremelanotide, compounded preparations, or research peptides, and to no specific telehealth platforms. The references page links only to the primary scientific and regulatory sources that underwrite the summaries.

What we do not claim

There are no doctors, pharmacists, nurses, nurse practitioners, or other healthcare staff behind this manual. The phrase 'qualified clinician' or 'state-licensed clinician' on these pages refers to the kind of clinician who would perform the evaluation in the published practice frame — not to anyone on staff here. There is no clinical staff because this is not a clinical operation, and there is no clinic, dispensing pharmacy, or patient-facing service.

The manual does not, and will not, sell bremelanotide, sell access to a prescribing clinician, refer patients to specific telehealth platforms, or run any intake or evaluation. It is a reference — a reading of publicly available scientific and regulatory documents — and nothing here is medical advice or a clinical recommendation.

On the FDA-approved product vs. compounded vs. research peptides

The manual distinguishes carefully throughout between the FDA-approved bremelanotide product (a specific 1.75 mg subcutaneous autoinjector manufactured under federal oversight) and other preparations marketed under the name 'PT-141'. The clinical data, pharmacokinetic profile, safety profile, and dosing guidance summarized here apply to the FDA-approved product. Compounded preparations are a separate regulatory category, evaluated under the FDA's evolving compounding framework. Research peptide vials are not FDA-evaluated products of any kind. This distinction matters and is noted on every page where the topic arises.